vs
Side-by-side financial comparison of AvalonBay Communities (AVB) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
AvalonBay Communities is the larger business by last-quarter revenue ($767.9M vs $699.9M, roughly 1.1× QuidelOrtho Corp). AvalonBay Communities runs the higher net margin — 9040.6% vs -104.7%, a 9145.3% gap on every dollar of revenue. On growth, AvalonBay Communities posted the faster year-over-year revenue change (3.7% vs -3.7%). AvalonBay Communities produced more free cash flow last quarter ($1.4B vs $-94.7M). Over the past eight quarters, AvalonBay Communities's revenue compounded faster (3.8% CAGR vs -2.9%).
AvalonBay Communities, Inc. is a publicly traded real estate investment trust that invests in apartments.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
AVB vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $767.9M | $699.9M |
| Net Profit | $166.0M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | 64.2% | -100.7% |
| Net Margin | 9040.6% | -104.7% |
| Revenue YoY | 3.7% | -3.7% |
| Net Profit YoY | -41.2% | -3583.4% |
| EPS (diluted) | $1.18 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $767.9M | — | ||
| Q3 25 | $766.8M | $699.9M | ||
| Q2 25 | $760.2M | $613.9M | ||
| Q1 25 | $745.9M | $692.8M | ||
| Q4 24 | $740.5M | $707.8M | ||
| Q3 24 | $734.3M | $727.1M | ||
| Q2 24 | $726.0M | $637.0M | ||
| Q1 24 | $712.9M | $711.0M |
| Q4 25 | $166.0M | — | ||
| Q3 25 | $381.3M | $-733.0M | ||
| Q2 25 | $268.7M | $-255.4M | ||
| Q1 25 | $236.6M | $-12.7M | ||
| Q4 24 | $282.1M | $-178.4M | ||
| Q3 24 | $372.5M | $-19.9M | ||
| Q2 24 | $253.9M | $-147.7M | ||
| Q1 24 | $173.4M | $-1.7B |
| Q4 25 | 64.2% | — | ||
| Q3 25 | 65.7% | -100.7% | ||
| Q2 25 | 67.6% | -29.4% | ||
| Q1 25 | 68.5% | 4.7% | ||
| Q4 24 | 63.1% | -14.2% | ||
| Q3 24 | 65.4% | 2.1% | ||
| Q2 24 | 66.6% | -18.4% | ||
| Q1 24 | 67.2% | -247.3% |
| Q4 25 | 9040.6% | — | ||
| Q3 25 | 49.7% | -104.7% | ||
| Q2 25 | 35.3% | -41.6% | ||
| Q1 25 | 31.7% | -1.8% | ||
| Q4 24 | 38.1% | -25.2% | ||
| Q3 24 | 50.7% | -2.7% | ||
| Q2 24 | 35.0% | -23.2% | ||
| Q1 24 | 24.3% | -239.9% |
| Q4 25 | $1.18 | — | ||
| Q3 25 | $2.68 | $-10.78 | ||
| Q2 25 | $1.88 | $-3.77 | ||
| Q1 25 | $1.66 | $-0.19 | ||
| Q4 24 | $1.99 | $-2.54 | ||
| Q3 24 | $2.61 | $-0.30 | ||
| Q2 24 | $1.78 | $-2.20 | ||
| Q1 24 | $1.22 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $187.2M | $98.1M |
| Total DebtLower is stronger | $9.3B | $2.5B |
| Stockholders' EquityBook value | $11.6B | $2.0B |
| Total Assets | $22.2B | $5.7B |
| Debt / EquityLower = less leverage | 0.80× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $187.2M | — | ||
| Q3 25 | $123.3M | $98.1M | ||
| Q2 25 | $102.8M | $151.7M | ||
| Q1 25 | $53.3M | $127.1M | ||
| Q4 24 | $108.6M | $98.3M | ||
| Q3 24 | $552.4M | $143.7M | ||
| Q2 24 | $545.8M | $107.0M | ||
| Q1 24 | $287.9M | $78.5M |
| Q4 25 | $9.3B | — | ||
| Q3 25 | $8.7B | $2.5B | ||
| Q2 25 | $8.7B | $2.1B | ||
| Q1 25 | $8.3B | $2.1B | ||
| Q4 24 | $8.1B | $2.1B | ||
| Q3 24 | $8.4B | $2.2B | ||
| Q2 24 | $8.4B | $2.2B | ||
| Q1 24 | $8.0B | $2.2B |
| Q4 25 | $11.6B | — | ||
| Q3 25 | $11.9B | $2.0B | ||
| Q2 25 | $11.9B | $2.8B | ||
| Q1 25 | $11.9B | $3.0B | ||
| Q4 24 | $11.9B | $3.0B | ||
| Q3 24 | $11.9B | $3.2B | ||
| Q2 24 | $11.7B | $3.2B | ||
| Q1 24 | $11.7B | $3.3B |
| Q4 25 | $22.2B | — | ||
| Q3 25 | $21.9B | $5.7B | ||
| Q2 25 | $21.8B | $6.4B | ||
| Q1 25 | $21.2B | $6.5B | ||
| Q4 24 | $21.0B | $6.4B | ||
| Q3 24 | $21.3B | $6.8B | ||
| Q2 24 | $21.0B | $6.7B | ||
| Q1 24 | $20.6B | $6.7B |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.73× | 1.23× | ||
| Q2 25 | 0.72× | 0.74× | ||
| Q1 25 | 0.70× | 0.70× | ||
| Q4 24 | 0.68× | 0.72× | ||
| Q3 24 | 0.70× | 0.68× | ||
| Q2 24 | 0.71× | 0.70× | ||
| Q1 24 | 0.68× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7B | $-45.5M |
| Free Cash FlowOCF − Capex | $1.4B | $-94.7M |
| FCF MarginFCF / Revenue | 183.5% | -13.5% |
| Capex IntensityCapex / Revenue | 34.1% | 7.0% |
| Cash ConversionOCF / Net Profit | 10.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.5B | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | — | ||
| Q3 25 | $477.0M | $-45.5M | ||
| Q2 25 | $377.8M | $-46.8M | ||
| Q1 25 | $415.9M | $65.6M | ||
| Q4 24 | $1.6B | $63.7M | ||
| Q3 24 | $486.2M | $117.9M | ||
| Q2 24 | $380.0M | $-97.9M | ||
| Q1 24 | $412.9M | $-700.0K |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $402.2M | $-94.7M | ||
| Q2 25 | $317.1M | $-84.3M | ||
| Q1 25 | $367.5M | $9.4M | ||
| Q4 24 | $1.4B | $16.5M | ||
| Q3 24 | $434.2M | $71.4M | ||
| Q2 24 | $333.0M | $-133.2M | ||
| Q1 24 | $375.4M | $-66.8M |
| Q4 25 | 183.5% | — | ||
| Q3 25 | 52.5% | -13.5% | ||
| Q2 25 | 41.7% | -13.7% | ||
| Q1 25 | 49.3% | 1.4% | ||
| Q4 24 | 191.0% | 2.3% | ||
| Q3 24 | 59.1% | 9.8% | ||
| Q2 24 | 45.9% | -20.9% | ||
| Q1 24 | 52.7% | -9.4% |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 9.8% | 7.0% | ||
| Q2 25 | 8.0% | 6.1% | ||
| Q1 25 | 6.5% | 8.1% | ||
| Q4 24 | 26.1% | 6.7% | ||
| Q3 24 | 7.1% | 6.4% | ||
| Q2 24 | 6.5% | 5.5% | ||
| Q1 24 | 5.3% | 9.3% |
| Q4 25 | 10.07× | — | ||
| Q3 25 | 1.25× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.76× | — | ||
| Q4 24 | 5.70× | — | ||
| Q3 24 | 1.31× | — | ||
| Q2 24 | 1.50× | — | ||
| Q1 24 | 2.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVB
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
